(Q36592621)

15 August 2017

1 reference

title

Atypical antipsychotics for neuropsychiatric symptoms of dementia: malignant or maligned? (English)

1 reference

15 August 2017

1 reference

2

Krista L Lanctôt

1 reference

15 August 2017

Nathan Herrmann

1

1 reference

15 August 2017

publication date

1 January 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

29

1 reference

15 August 2017

issue

10

1 reference

15 August 2017

page(s)

833-843

1 reference

Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629100-00002

Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629100-00002

A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629100-00002

Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629100-00002

Lower incidence of tardive dyskinesia with risperidone compared with haloperidol in older patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629100-00002

Do neuroleptic drugs hasten cognitive decline in dementia? Prospective study with necropsy follow up.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002018-200629100-00002

Consensus statement on improving the quality of mental health care in U.S. nursing homes: management of depression and behavioral symptoms associated with dementia

21 January 2018

1 reference

12 December 2020

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

12 December 2020

Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone

1 reference

12 December 2020

Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group

1 reference

12 December 2020

FDA warns antipsychotic drugs may be risky for elderly

1 reference

12 December 2020

Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study

1 reference

12 December 2020

Psychotropic drugs and risk of recurrent falls in ambulatory nursing home residents

1 reference

12 December 2020

Lower mortality in geriatric patients receiving risperidone and olanzapine versus haloperidol: preliminary analysis of retrospective data

1 reference

12 December 2020

A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia.

1 reference

12 December 2020

Conventional and Atypical Antipsychotics and the Risk of Hospitalization for Ventricular Arrhythmias or Cardiac Arrest

1 reference

12 December 2020

Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial

1 reference

12 December 2020

Risperidone and falls in ambulatory nursing home residents with dementia and psychosis or agitation: secondary analysis of a double-blind, placebo-controlled trial

1 reference

12 December 2020

Psychotropic medication and stroke outcome

1 reference

12 December 2020

Risk of death in elderly users of conventional vs. atypical antipsychotic medications

1 reference

12 December 2020

Comparison of incidence rates of cerebrovascular accidents and transient ischaemic attacks in observational cohort studies of patients prescribed risperidone, quetiapine or olanzapine in general practice in England including patients with dementia

1 reference

12 December 2020

Cerebrovascular events among elderly nursing home patients treated with conventional or atypical antipsychotics

1 reference

12 December 2020

Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials

1 reference

12 December 2020

Exploring the association between atypical neuroleptic agents and diabetes mellitus in older adults

1 reference

12 December 2020

Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease

1 reference

12 December 2020

Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias

1 reference

12 December 2020

Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia

1 reference

12 December 2020

Effect of risperidone on QT interval and QT dispersion in the elderly

1 reference

12 December 2020

Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine

1 reference

12 December 2020

Effects of olanzapine on lipid abnormalities in elderly psychotic patients

1 reference

12 December 2020

Atypical antipsychotic medications and risk of falls in residents of aged care facilities

1 reference

12 December 2020

Long-term efficacy of olanzapine in the control of psychotic and behavioral symptoms in nursing home patients with Alzheimer's dementia

1 reference

12 December 2020

Weight variance associated with atypical neuroleptics in nursing home dementia patients

1 reference

12 December 2020

Atypical antipsychotics and risk of cerebrovascular accidents.

1 reference

12 December 2020

Effect of antipsychotic withdrawal on behavior and sleep/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study. The Bergen District Nursing Home Study

1 reference

12 December 2020

Do atypical antipsychotics cause stroke?

1 reference

12 December 2020

Antipsychotic-Induced movement disorders in the elderly: epidemiology and treatment recommendations

1 reference

12 December 2020

Drug-induced prolongation of the QT interval

1 reference

12 December 2020

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

12 December 2020

Antipsychotic use in the elderly: shifting trends and increasing costs.

1 reference

12 December 2020

Benzodiazepines and the risk of falls in nursing home residents.

1 reference

12 December 2020

Efficacy and safety of neuroleptics in behavioral disorders associated with dementia.

1 reference

12 December 2020

Antipsychotic and antidepressant drug use in the elderly and the risk of venous thromboembolism

1 reference

12 December 2020

No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment.

1 reference

12 December 2020

A 3-month, randomized, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cutoff is a predictor of clinical outcome.

1 reference

12 December 2020

Atypical antipsychotic drugs and risk of ischaemic stroke: population based retrospective cohort study

1 reference

12 December 2020

Recommendations for the management of behavioral and psychological symptoms of dementia.

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials.

1 reference

12 December 2020

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.

1 reference

12 December 2020

Use of selective serotonin-reuptake inhibitors or tricyclic antidepressants and risk of hip fractures in elderly people

1 reference

12 December 2020

Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment

1 reference

12 December 2020

Atypical Antipsychotics and Parkinsonism

1 reference

12 December 2020

Differential effects of risperidone, olanzapine, clozapine, and conventional antipsychotics on type 2 diabetes: findings from a large health plan database

1 reference

12 December 2020

Using antipsychotic agents in older patients

1 reference

12 December 2020

Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home.

1 reference

12 December 2020

Practice guideline for the treatment of patients with Alzheimer's disease and other dementias of late life. American Psychiatric Association

1 reference

12 December 2020

Antipsychotics and the risk of sudden cardiac death

1 reference

12 December 2020

International Multisite Double-Blind Trial of the Atypical Antipsychotics Risperidone and Olanzapine in 175 Elderly Patients With Chronic Schizophrenia

1 reference

12 December 2020

A randomized, placebo-controlled trial of the discontinuation of long-term antipsychotics in dementia

1 reference

12 December 2020

Clozapine and olanzapine, but not conventional antipsychotics, increase insulin release in vitro

1 reference

12 December 2020

Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence

1 reference

12 December 2020

Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia

1 reference

12 December 2020

10.2165/00002018-200629100-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

15 August 2017

1044734365

0 references

1 reference